Atezolizumab
Tecentriq (atezolizumab) is a prescription monoclonal antibody made by Genentech, Inc., given intravenously to treat certain cancers. It works by blocking PD-1 receptors to help the immune system fight tumors. Available as a 1200 mg/20 mL solution in single-use vials. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Tecentriq (atezolizumab) is a prescription monoclonal antibody made by Genentech, Inc., given intravenously to treat certain cancers. It works by blocking PD-1 receptors to help the immune system fight tumors. Available as a 1200 mg/20 mL solution in single-use vials. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Atezolizumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Atezolizumab — ANDA 761347 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761347"
}
]
|
| identifier | ANDA761347 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"health-care",
"pharmaceuticals",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Atezolizumab |
